BoomRx for clinics: who actually buys and uses it

An owner should evaluate BoomRx on landed cost and predictability. Because pricing is confirmed after signup, the owner cannot compare per-vial rates on boomrx.com before onboarding, so the key questions are what the all-in cost is after the $30 shipping fee and whether competitive pricing holds across refill cycles. An operations lead should evaluate the daily workflow: how many portals it actually replaces, how order status reaches patients through automated SMS updates, and how live-time data reporting supports procurement decisions.

A prescriber should evaluate clinical accuracy and speed: whether SIG entry is fast, whether licensure and state routing are handled before submission, and whether EMR or API integrations reduce redundant data entry. Each role's risk is different, but they share one dependency — the platform behavior around pricing visibility, patient-linked checkout, and per-line audit — which is exactly where ordering platforms diverge.

Fizy Health serves the same three roles but rearranges what each sees. The owner gets pass-through per-vial 503A cost on every catalog and cart line before checkout, with a disclosed facilitation fee — so margin is visible without waiting on portal pricing. The operations lead gets one clinic cart that batches every patient's order for refill day, with cart validation catching invalid SIGs, prescriber state mismatches, and stock gaps before payment.

The prescriber gets directions and licensure checked before the order is submitted, reducing post-pay rejections, plus support tickets that stay in the app tied to the order and patient. Same category as BoomRx on 503A ordering — but the owner, operator, and prescriber each get more decided before money moves, and every line ties to a patient with HIPAA audit.